Skip to content
  • info@qps.com
  • English
qps-30-logo-144ppi
  • Company
  • Locations
    • USA
      • Delaware
      • Miami
      • Missouri
    • Europe
      • The Netherlands
      • Austria
    • Taiwan
      • CTPS
      • NKSP
      • Qualitix
    • India
  • Insights
Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt
  • Services
      Bioanalysis >
      • Assay Finder
      • Biomarkers and Translational Medicine
      • Biotherapeutics
      • Cell and Gene Therapy
      • CLIA
      • Genomics
      • ICP-MS (Mass Spectrometry)
      • Small Molecules
      Preclinical Services >
      • DMPK
      • Biotransformation
      • Micro Autoradiography (MARG)
      • Preclinical DDI Studies
      • Protein Binding
      • Radiolabeled ADME
      • Quantitative Whole-Body Autoradiography (QWBA)
      • IND Package
      • Pharmacology
      • Toxicology
      Lab Services >
      • Leukopak Services
      • Peripheral Blood Mononuclear Cells (PBMCs)
      Clinical Services >
      • Early Stage Clinical Trials
      • Clinical Research Services
      • Project Management and Site Monitoring
      • Site Identification and Qualification
      • Global Medical Affairs
      • Medical Writing Services
      • Pharmacovigilance
      • Global Regulatory Affairs
      • Central Safety Lab
      • Clinical Trial Kits
      • Clinical Biostatistics Consultancy
      • Clinical Data Management
      • Study Recruitment
  • Resources
    • Our Science
      • Expert Interviews
      • Podcasts
      • Scientific Posters
      • Scientific Reference Articles
      • Thought Leadership
      • Webinars
      • White Papers
    • Our Expertise
      • Dermatology
        • Dermal and Transdermal
      • Endocrinology
      • Inflammatory Bowel Disease
      • Neuropsychiatry
      • Obesity Clinical Trials
      • Oncology Clinical Trials
      • Rheumatology
      • Vaccines
      • Women’s Health
    • Services Materials
      • Brochures
        • Brochures – Chinese
        • Brochures – Japanese
        • Brochures – Korean
      • Case Studies
      • eBooks
      • Ultimate Guides
        • Oncology
        • Oligonucleotides
        • Gene Therapy
      • Videos
    • Guidance Documents
  • Blog
    • Infographics
  • Careers
  • Contact
QPS Logo
qps-30-logo-144ppi
  • Company
  • Locations
    • USA
      • Delaware
      • Miami
      • Missouri
    • Europe
      • The Netherlands
      • Austria
    • Taiwan
      • CTPS
      • NKSP
      • Qualitix
    • India
  • Insights
  • Services
    • Bioanalysis
      • Assay Finder
      • Biomarkers and Translational Medicine
      • Biotherapeutics
      • Cell and Gene Therapy
      • CLIA
      • Genomics
      • ICP-MS (Mass Spectrometry)
      • Small Molecules
    • Preclinical Services
      • DMPK
        • Biotransformation
        • Micro Autoradiography (MARG)
        • Preclinical DDI Studies
        • Protein Binding
        • Radiolabeled ADME
        • Quantitative Whole-Body Autoradiography (QWBA)
      • IND Package
      • Pharmacology
      • Toxicology
    • Lab Services
      • Leukopak Services
      • Peripheral Blood Mononuclear Cells (PBMCs)
    • Clinical Services
      • Early Stage Clinical Services
      • Clinical Research Services
        • Project Management and Site Monitoring
        • Site Identification and Qualification
        • Global Medical Affairs
          • Medical Writing Services
          • Pharmacovigilance
        • Global Regulatory Affairs
        • Central Safety Lab
        • Clinical Trials Kits
        • Clinical Biostatistics Consultancy
        • Clinical Data Management
        • Study Recruitment
  • Resources
    • Our Science
      • Expert Interviews
      • Podcasts
      • Scientific Posters
      • Scientific Articles
      • Thought Leadership
      • Webinars
      • White Papers
    • Our Expertise
      • Dermatology
        • Dermal and Transdermal
      • Endocrinology
      • Inflammatory Bowel Disease
      • Neuropsychiatry
      • Obesity Clinical Trials
      • Oncology Clinical Trials
      • Rheumatology
      • Vaccines
      • Women’s Health
    • Service Materials
      • Brochures
        • Brochures – Chinese
        • Brochures – Japanese
        • Brochures – Korean
      • Case Studies
      • eBooks
      • Ultimate Guides
        • Oncology
        • Oligonucleotides
        • Gene Therapy
      • Videos
    • Guidance Documents
  • Blog
    • Blog Infographics
  • Careers
  • Contact

Blog

Home / The History of Gene Therapy
QPS-logo-white-tagline

The History of Gene Therapy

  • QPS
  • July 5, 2023
  • Gene Therapy

The promise and potential of gene therapy have gone through several iterations since the 1960s, when scientists first hypothesized that introducing DNA sequences into their patients’ cells might be able to cure certain genetic disorders. Tracking the history of gene therapy from the 1960s until today is a snapshot of scientific breakthroughs, setbacks, and milestones.

Gloved hand using tweezers to pull out a section of DNA

A Brief Overview of the History of Gene Therapy

Although the concepts of gene therapy initially arose in the 1960s, scientists didn’t see significant technological progress for the first 20 or so years. Real breakthroughs in recombinant DNA technology began to occur in earnest in the early 1980s, beginning with the publication of a paper that demonstrated, for the first time, that it was possible to use a virus as a mechanism for inserting genes into stem cells.

The first major success story in the history of gene therapy occurred in 1990 with Ashanthi de Silva, a 4-year-old girl diagnosed with severe combined immunodeficiency (SCID) caused by a rare genetic disorder, adenosine deaminase (ADA) deficiency. Doctors successfully used a disabled virus to introduce a healthy ADA gene into her blood cells. Today, de Silva is in her 30s and a rare disease advocate. The history of gene therapy officially had its first major breakthrough.

But that same decade also saw tragic setbacks. In a 1999 clinical trial, Jesse Gelsinger, an 18-year-old, began gene therapy for a rare genetic condition known as ornithine transcarbamylase deficiency. But the treatment triggered a catastrophic immune reaction, and only four days after receiving treatment, Gelsinger died. The tragedy shocked and sobered both the scientific community and the general public, prompting investigations into the safety measures and regulatory oversight of other gene therapy trials in progress and grinding many developments in the field to a halt.

By the early 2010s, though, scientists had improved the viral vectors delivering gene therapies, allowing them to more precisely and safely target specific genes without triggering dangerous immune responses. 

FDA Eyes New Policies

In the past decade, the pace of successful gene therapy breakthroughs has picked up steam across the globe. New methods for delivering or repairing genes — like gene editing and base editing — and other genetic therapies have created promising alternative pathways for treatment, and today, over 400 gene therapy studies are active worldwide.

In the U.S., the number of applications for new gene therapies has been so immense that the FDA is looking for better strategies to manage the influx and expedite the development and testing process so that innovative therapies can be brought to patients more quickly. 

One of the people behind this push is Peter Marks, director of the Center for Biologics Evaluation and Research (CBER), a division within the FDA. Marks has been frustrated by the slow pace of developing and testing new gene therapies. As Marks emphasizes, “I don’t think we have a really long time to play around.”

Transforming the Environment

The way forward, Marks believes, is by transforming the environment, accelerating endpoints, and supporting regulatory flexibility. To that end, the CBER has replaced the Office of Tissues and Advanced Therapies (OTAT) with a much larger office: the Office of Therapeutic Products (OTP). The six offices of the OTP oversee 14 divisions and 33 branches, and with an expanded staff, the office aims to expedite the assessment and approval process for gene therapies. 

Marks has also proposed that the CBER borrow from innovative strategies used in another division of the FDA, the Oncology Center of Excellence (OCE), which include an “accelerated approval pathway for promising therapies.” CBER also plans to work towards better cooperation between international regulatory authorities.

The process has already begun, with the FDA recently accelerating the approval of QalsodyTM (tofersen), a treatment for amyotrophic lateral sclerosis (ALS). 

Overall, Marks expects that the necessary environmental transformation — accelerating the pace of gene therapy research while working to bring costs down — will take two to three years. The end goal is to provide life-saving therapies to patients who need them. As Marks summarizes, “If we get it right, it will make a huge difference in the bio-economy.”

QPS is a GLP- and GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical and clinical drug research development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,100+ employees in the U.S., Europe and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in neuropharmacology, DMPK, toxicology, bioanalysis, translational medicine and clinical development. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.

Facebook
Twitter
LinkedIn
Previous Could Deep Brain Stimulation Restore Memory After Brain Injury? Next Donanemab Shows Promise in Slowing Cognitive Decline in Alzheimer’s Disease

Time is of the essence in Drug Development.

Contact the QPS Business Development Team Today!

Your link to a rewarding career.

Join the QPS team and be part of our growing organization.

Submit Your Resume

About qps

  • Mission, Vision, and Values
  • QPS History
  • Bioanalysis Milestones
  • Locations
  • Meet Our People
  • Blog
  • Careers
  • Privacy Policy
  • Mission, Vision, and Values
  • QPS History
  • Bioanalysis Milestones
  • Locations
  • Meet Our People
  • Blog
  • Careers
  • Privacy Policy

Preclinical Services

  • Assay Finder
  • DMPK
  • IND Package
  • Pharmacology
  • Toxicology
  • Assay Finder
  • DMPK
  • IND Package
  • Pharmacology
  • Toxicology

Clinical Services

  • Early Phase Clinical Trials
  • Leukopak Services
  • Global Medical Affairs
  • Global Regulatory Affairs
  • Therapeutic Areas
  • Early Phase Clinical Trials
  • Leukopak Services
  • Global Medical Affairs
  • Global Regulatory Affairs
  • Therapeutic Areas

Resources

  • Brochures
  • Case Studies
  • Conferences
  • eBooks
  • Guidance Documents
  • Milestones
  • Scientific Posters
  • Scientific Reference Articles
  • Thought Leadership
  • Videos/Webinars
  • White Papers
  • Brochures
  • Case Studies
  • Conferences
  • eBooks
  • Guidance Documents
  • Milestones
  • Scientific Posters
  • Scientific Reference Articles
  • Thought Leadership
  • Videos/Webinars
  • White Papers

Headquarters Location

Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711

  • +1 512 350 2827
  • +1 302 369 5602
  • info@qps.com

Connect with us

Linkedin-in Youtube Facebook-f Instagram
download-ios
download-google
qps-assay-finder-black

Subscribe To Our Blog

"*" indicates required fields

Name
Address
Confirmation*
This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.

Copyright © 2025 · QPS Holdings. All Rights Reserved | Web Design by 417 Marketing.
Contact Us
Scroll to Top

Notifications